Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients
Authors' conclusion
New BL/BLI combinations and cefiderocol represent long-awaited options for improving the management of DTR-GNB infections.
Study context
- Population
- Critically ill patients with Gram-negative bacteria infections with difficult-to-treat resistance (DTR-GNB)
Methodological detailssystematic literature search, Search of PUBMED and Cochrane Library, English-language, inception to November 15, 2022
- Systematic literature search
- Search of PUBMED and Cochrane Library, English-language, inception to November 15, 2022
Main finding
As reported in the abstract
- New BL/BLI combinations and cefiderocol showed relevant clinical success rates and reduced renal risk in severe infections historically treated with polymyxin- and/or aminoglycoside-based regimens
- Limited clinical evidence in critically ill patients
- Extended infusion (except imipenem-relebactam) may be indicated for DTR-GNB with high minimal inhibitory concentrations and/or augmented renal clearance
Original publication
Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients. Ann Intensive Care. Published 18 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →